Aksjekapitalforhøyelse

DiaGenic ASA meldte 26. november 2009 om emisjon av 12,5 millioner nye aksjer til tegningskurs NOK 2,75 per aksje. Aksjekapitalen er nå registrert i Foretaksregisteret. Ny aksjekapital i DiaGenic ASA er NOK 3 336 826, fordelt på 66 736 520 aksjer, hver pålydende NOK 0,05. Selskapets vedtekter er oppdatert i samsvar med kapitalforhøyelsen. Oppdatert firmaattest følger vedlagt. Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

Om oss

DiaGenic ASA is an innovative Norwegian life sciences company founded in 1998 and listed on the Oslo Stock Exchange. DiaGenic develops patient-friendly tests for the early diagnosis of devastating diseases where early intervention is crucial for successful treatment. DiaGenic’s patented method is based on identifying disease-specific gene signatures from easily available sample material such as blood. DiaGenic's strategy is to work with research and technology partners to develop a pipeline of assays for commercialisation by major diagnostics companies. Currently DiaGenic’s first two tests for the early detection of breast cancer and Alzheimer’s disease are on track to enter extensive clinical trials during 2007. The company has been awarded substantial development grants as part of the Norwegian Research Council’s FUGE programme.

Abonner

Dokumenter og linker